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ABSTRACT
Introduction: Non-valvular atrial fibrillation
(NVAF) is often accompanied by multiple
comorbid conditions, which increase the asso-
ciated risks and complexity of patient man-
agement. This study evaluated the risk of
stroke/systemic embolism (SE) and major
bleeding (MB) among multimorbid patients
with NVAF who were prescribed non-vitamin K
antagonist oral anticoagulants (NOACs) or
warfarin.
Methods: A retrospective study of patients with
NVAF and high multimorbidity who initiated
apixaban, dabigatran, rivaroxaban, or warfarin
from 1 January 2013 to 30 September 2015 was
conducted using five insurance claims data-
bases. Multimorbidity was defined as six or
more comorbid conditions, and 1:1 propensity
score matching (PSM) was conducted between
the NOAC-warfarin and NOAC-NOAC cohorts.
Cox proportional hazard models were used to
evaluate the hazard ratios of stroke/SE and MB.
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Results: Of the NVAF population (n = 466,991),
33.4% (n = 155,959) had multimorbidity,
including 36,921 apixaban, 10,248 dabigatran,
45,509 rivaroxaban, and63,281warfarinpatients.
Compared towarfarin, apixaban and rivaroxaban
were associated with a lower risk of stroke/SE
(hazard ratio [HR] 0.63, 95% CI 0.54–0.74; HR
0.70, 95% CI 0.64–0.77, respectively). Apixaban
anddabigatranwereassociatedwitha lower riskof
MB (HR 0.61, 95% CI 0.56–0.67; HR 0.75, 95% CI
0.66–0.86, respectively) and rivaroxaban was
associated with a higher risk ofMB (HR 1.06, 95%
CI 1.01–1.12) compared to warfarin.
Conclusions: Among patients with NVAF and
six or more comorbid conditions, NOACs were
associated with varying risk of stroke/SE and MB
compared to warfarin and to each other. Rather
than a ‘‘one drug fits all’’ approach, our results
may be useful for appropriate OAC treatment
for multimorbid patients.
Keywords: Anticoagulation; Bleeding; Multi-
morbidity; Outcomes; Stroke
Key Summary Points
Why carry out this study?
The presence of multiple comorbid
conditions increases the risk of adverse
clinical outcomes in patients with AF.
This study evaluates the safety and
effectiveness of non-vitamin K antagonist
oral anticoagulants (NOACs) versus
warfarin among patients with AF and
multiple comorbid conditions.
What was learned from the study?
In this multimorbid subgroup of patients
with AF, NOACs were associated with
varying risks of stroke/SE and major
bleeding compared to warfarin.
These results may help inform treatment
selection in this high-risk subgroup of
patients with AF by allowing clinicians to
choose the safest and most effective
treatment according to the patient
comorbidity burden.
DIGITAL FEATURES
This article is published with digital features,
including a summary slide, to facilitate under-
standing of the article. To view digital features
for this article go to https://doi.org/10.6084/
m9.figshare.14261612.
INTRODUCTION
Atrial fibrillation (AF) is the most common
serious cardiac arrhythmia, affecting 2–3% of
the population in North America [1]. Previ-
ously, vitamin K antagonists, such as warfarin,
were the most commonly prescribed therapeu-
tic agents for AF. However, the needs for peri-
odic patient monitoring and frequent dose
adjustment increase the patient burden of
treatment [2]. Non-vitamin K antagonist oral
anticoagulants (NOACs: apixaban, dabigatran,
edoxaban, and rivaroxaban) offer a non-infe-
rior, safe, effective treatment choice for stroke
prevention in patients with non-valvular atrial
fibrillation (NVAF) without the restrictions of
conventional therapy [3, 4].
Multimorbidity, often defined as the coexis-
tence of two or more comorbid conditions, may
provide a proxy for identifying chronic disease
burden and functional status and may influence
treatment selection [5]. More than two-thirds of
Medicare patients have two or more comor-
bidities; the median number is six, with AF
being the 11th most common [6]. Multimor-
bidity is associated with an increased risk of AF,
cerebrovascular events, and mortality, with the
risk increasing in accordance with the number
of long-term conditions [7, 8]. Furthermore,
patients with multimorbidity receiving oral
anticoagulation therapy are associated with an
increased risk of stroke relative to patients
without multimorbidity who receive anticoag-
ulation therapy [6]. Indeed, ad hoc results from
the ARISTOTLE trial found that the risk of major
bleeding (MB) rises by approximately 15% for
each singular comorbidity [9]. However, despite
the need for a safe treatment in this patient
population, anticoagulants are generally
underused—fewer than half of older adults with
AF, who are generally multimorbid, receive
Adv Ther (2021) 38:3166–3184 3167
anticoagulants even without contraindications
[6].
There have been very few observational
studies comparing NOACs and warfarin among
patients with NVAF and multimorbidity. This
ARISTOPHANES (Anticoagulants for Reduction
In Stroke: Observational Pooled Analysis on
Health Outcomes and Experience of Patients;
NCT03087487) sub-study compared the risk of
stroke/SE and MB among multimorbid patients
with NVAF who were newly prescribed apixa-
ban, dabigatran, rivaroxaban, or warfarin.
METHODS
Data Sources
This retrospective observational analysis uti-
lized Medicare fee-for-service data from the US
Centers for Medicare & Medicaid Services (CMS)
and data from four US commercial claims
databases: the IBM MarketScan Commercial
Claims and Encounter Database, the IQVIA
PharMetrics PlusTM Database, the Optum Clin-
formaticsTM Data Mart, and the Humana
Research Database. Previously published articles
include detailed descriptions of the datasets, the
rationale for the pooling process, and the
approaches to minimizing potential patient
record duplicates across data sources [10, 11]. To
avoid potential duplicates, patients with Medi-
care supplemental plans in MarketScan and
PharMetrics data were excluded from the study
because those patients may also have Medicare
Part A and Part B coverage. For Optum and
Humana, beneficiaries aged 65 years or more are
enrolled in Medicare Advantage plans but are
not covered in Medicare data. There is a possi-
bility that employer-based commercial claims
datasets may contain duplicate patient records
when pooled together; however, the number of
duplicates is likely to be small at an estimated
0.5%.
Patient Selection
For this study, multimorbidity was defined
as the presence of six or more comorbid
conditions, not including AF, among the 17
conditions listed in Tables 1 and 2 [9], based on
both the distribution of comorbidities as well as
the ARISTOTLE multimorbidity subgroup anal-
ysis, the only prior published analysis based on
a phase 3 randomized controlled trial (RCT) for
NOACs in a multimorbid population [9]. The
present study utilized the same count for high
multimorbidity as seen in the ARISTOTLE sub-
group analysis. Patients with NVAF and multi-
morbidity were selected if they had at least one
pharmacy claim for apixaban, dabigatran,
rivaroxaban, or warfarin between 1 January
2013 to 30 September 2015 (identification per-
iod). Edoxaban was not included in the final
analysis because of the small sample size. For
patients with a NOAC claim during the identi-
fication period, the first NOAC prescription date
was designated as the index date; for patients
with no NOAC claim during the identification
period, the first warfarin prescription date was
designated as the index date. Patients were
required to have an AF diagnosis before the
index date and have continuous medical and
pharmacy health plan enrollment for at least
12 months pre-index date.
Patients treated with an OAC within
12 months pre-index date were excluded.
Patients were also excluded if they had evidence
of valvular heart disease, venous thromboem-
bolism, transient AF, heart valve replace-
ment/transplant during the baseline period,
pregnancy during the study period, or hip or
knee replacement surgery within 6 weeks pre-
index date. Additional exclusion criteria are
shown in Fig. 1.
Outcome Measures
The primary outcomes measured were time to
first stroke/SE and time to first MB. Stroke/SE
was stratified by ischemic stroke, hemorrhagic
stroke, and systemic embolism (SE). MB was
stratified by gastrointestinal (GI) bleeding,
intracranial hemorrhage, and bleeding at other
key sites (Supplementary Table S1) [12, 13].
Outcomes were based on hospitalizations with
stroke/SE or MB as the principal or first-listed
diagnosis. The follow-up period ranged from
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1 day post-index date to the first of 30 days after
discontinuation, switch date, death, end of
continuous medical or pharmacy plan enroll-
ment, or end of study.
Statistical Methods
Propensity score matching (PSM) was con-
ducted between NOAC and warfarin cohorts
and between the NOAC cohorts. Patients were
matched 1:1 in each dataset based on the
propensity scores generated by logistic regres-
sion using demographics, Charlson Comorbid-
ity Index (CCI) scores [14], comorbidities that
were documented risk factors for stroke/SE or
MB, and baseline co-medications. Patients were
matched by nearest neighbor matching without
replacement using a caliper of 0.01. Covariate
balance was checked through standardized dif-
ferences, with a threshold of 10% [15]. Patients
from the five matched datasets were pooled for
the final analysis.
Risk of stroke/SE and risk of MB were evalu-
ated using Cox proportional hazard models,
with robust sandwich estimates (a = 0.05) [16].
OAC treatment was included as the indepen-
dent variable; no other covariates were included
as the cohorts were balanced.
All statistical analyses were performed using
SAS version 9.4.
Subgroup Analyses
An interaction analysis was conducted between
treatment and comorbidity level among
patients with 6–8 comorbidities vs patients with
9? comorbidities. The statistical significance
(p\ 0.10) of the interaction between treatment
and comorbidity level was evaluated. Further,
PSM and Cox proportional hazard models were
separately completed for patients prescribed
standard dose NOACs (apixaban 5 mg, dabiga-
tran 150 mg, rivaroxaban 20 mg) and low dose
NOACs (apixaban 2.5 mg, dabigatran 75 mg,
rivaroxaban 10 or 15 mg).
Compliance with Ethics Guidelines
Since the core study described herein did not
involve the collection, use, or transmittal of
individual identifiable data, institutional review
board (IRB) approval to conduct this study was
not required. The security of the data meets the
requirements of the Health Insurance Portabil-
ity and Accountability Act (HIPAA) of 1996. The
study protocol was reviewed and determined to
be exempt from the Office for Human Research
Protections (OHRP’s) Regulations for the Pro-
tection of Human Subjects (45 CFR 46) under
the following category: Exemption 4: Research
involving the collection or study of existing
data, documents, records, pathological speci-
mens, or diagnostic specimens, if these sources
are publicly available or if the information is
recorded by the investigator in such a manner
that subjects cannot be identified, directly or
through identifiers linked to the subjects.
RESULTS
After applying the selection criteria, 33.4%
(n = 155,959) of the NVAF population newly
initiated on OACs (n = 466,991) had multi-
morbidity; 36,921 (23.7%) initiated apixaban,
10,248 (6.6%) dabigatran, 45,509 (29.2%)
rivaroxaban, and 63,281 (40.6%) warfarin
(Fig. 1). The mean number of comorbidities
ranged from 7.5 to 7.8 across the drug cohorts.
Before PSM, apixaban patients were older and
warfarin patients had higher CCI, CHA2DS2-
VASc, and HAS-BLED scores compared to NOAC
patients (Supplementary Table S2).
The unadjusted incidence rates of stroke/SE
per 100 person-years were 3.7 (warfarin), 2.4
(apixaban), 2.8 (dabigatran), and 2.4 (rivaroxa-
ban). The unadjusted rates for MB per 100 per-
son-years were 11.5 (warfarin), 6.9 (apixaban),
7.2 (dabigatran), and 10.5 (rivaroxaban) (Sup-
plementary Table S3).
After PSM, 34,658 apixaban-warfarin, 10,027
dabigatran-warfarin, and 40,601 rivaroxaban-
warfarin patient pairs were studied. Matching
bFig. 1 Study selection. AF atrial fibrillation; Clinical
Modification, OAC oral anticoagulant, VTE venous
thromboembolism
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for NOAC comparisons included 9962 patient
pairs for the apixaban-dabigatran, 35,126 pairs
for the apixaban-rivaroxaban, and 10,156 pairs
for the dabigatran-rivaroxaban cohorts (Fig. 1).
Coronary artery disease, hypertension, and GI
disorders were among some of the most preva-
lent comorbid conditions. The baseline charac-
teristics of the matched populations are shown
in Tables 1 and 2.
NOAC vs Warfarin Comparisons
Compared to warfarin, apixaban and rivaroxa-
ban were associated with a lower risk of stroke/
SE (apixaban: hazard ratio [HR] 0.63, 95% con-
fidence interval [CI] 0.54–0.74; rivaroxaban: HR
0.70, 95% CI 0.64–0.77). Dabigatran was asso-
ciated with a similar risk of stroke/SE (HR 0.91,
95% CI 0.75–1.10) compared to warfarin.
Apixaban and dabigatran were associated with a
lower risk of MB compared to warfarin (HR 0.61,
95% CI 0.56–0.67; HR 0.75, 95% CI 0.66–0.86,
respectively) while rivaroxaban patients had a
higher risk of MB (HR 1.06, 95% CI 1.01–1.12;
Fig. 2a).
NOAC vs NOAC Comparisons
Compared to dabigatran, apixaban was associ-
ated with a lower risk of stroke/SE (HR 0.81,
95% CI 0.65–1.00) and MB (HR 0.82, 95% CI
0.69–0.98). Dabigatran was associated with a
higher risk of stroke/SE versus rivaroxaban (HR
1.29, 95% CI 1.02–1.62). Apixaban and dabiga-
tran were associated with lower risks of MB
versus rivaroxaban (HR 0.57, 95% CI 0.52–0.63;
HR 0.72, 95% CI 0.64–0.81, respectively)
(Fig. 2b). The Kaplan–Meier curves for cumula-
tive incidence rates of stroke/SE and MB in the
matched populations are shown in Supple-
mentary Figs. S1A–S1L.
Subgroup Analyses
Significant interactions were observed for
treatment and number of comorbidities among
some of the analyses for stroke/SE and MB. For
apixabanvswarfarinandapixabanvs rivaroxaban,
patients with 6–8 comorbidities experienced a
greater relative magnitude of reduction in the
risk of MB compared to patients with 9?
comorbidities (Tables 3 and 4). A significant
interaction was also found for apixaban vs
rivaroxaban for stroke/SE (p = 0.064) where
apixaban patients with 6–8 comorbidities had a
similar risk of stroke/SE, but apixaban patients
with 9? comorbidities trended towards a lower
risk of stroke/SE compared with rivaroxaban
patients (Table 4). The results of the dose anal-
yses were generally consistent with the main
analysis. In the standard dose comparison, all
NOACs demonstrated a lower risk of stroke/SE
compared to warfarin (Supplementary Figs. S2
and S3).
DISCUSSION
This ARISTOPHANES subgroup analysis is the
largest study to date that evaluates the effec-
tiveness and safety of OAC treatment in a
multimorbid (at least six comorbidities) patient
population with NVAF. Overall, NOACs were
found to be associated with varying risk of
stroke/SE and MB compared to warfarin and
differential risk of stroke/SE and MB was also
observed between NOACs. Further analyses in
key subgroups, including NOAC low- and stan-
dard-dose populations and patients with 6–8 vs
9? comorbidities, showed generally consistent
findings.
Multimorbidity is common in patients with
NVAF, and proportionally becoming more
prevalent in recent years [17]. The presence of
multimorbidity is associated with an increased
risk of stroke, bleeding, and death [17]. The
results of the present study are similar to the
findings from related post hoc analyses of the
ARISTOTLE trial. Therein, patients were inclu-
ded on the basis of the number of comorbidities
and classified as no multimorbidity (0–2
cFig. 2 Incidence rates and hazard ratios for stroke and
major bleeding: a NOACs vs warfarin; b NOACs vs
NOACs. CI confidence interval, GI gastrointestinal,
NOAC non-vitamin K antagonist oral anticoagulant, SE
systemic embolism. aThe upper confidence interval was
rounded from 0.999 to 1
Adv Ther (2021) 38:3166–3184 3177
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comorbidities), moderate multimorbidity (3–5
comorbidities), and high multimorbidity (at
least 6 comorbidities), and the risks of stroke/SE
and MB were elevated for patients in the high
and moderate multimorbidity groups compared
with the no multimorbidity group [9]. The
ARISTOTLE post hoc analysis also found that
multimorbid apixaban patients trended toward
a lower risk of stroke/SE and MB compared to
warfarin, which is consistent with both the
main trial results and the present study [9].
Few real-world retrospective studies have
evaluated the impact of OAC treatment in
patients with AF and multimorbidity. One
study done by Mentias et al. assessed the effec-
tiveness of dabigatran, rivaroxaban, and war-
farin among Medicare patients with AF where
multimorbidity was indicated by CHA2DS2--
VASc, HAS-BLED, and Gagne comorbidity
scores rather than number of comorbid condi-
tions at baseline [18]. Across the three comor-
bidity scores, the authors found that standard-
dose dabigatran patients did not have a signifi-
cantly different risk of stroke or MB compared
to warfarin. This is inconsistent with the results
of both the standard-dose subgroup analysis of
this study and results from the RE-LY trial,
which showed that dabigatran had a signifi-
cantly lower risk of stroke/SE and MB compared
to warfarin [19]. Mentias et al. (2018) found that
standard-dose rivaroxaban patients had a
higher risk of MB compared to dabigatran
patients across all three scores, which is con-
sistent with results of our main analysis and
standard-dose subgroup analysis [18]. The dis-
crepancy in trends may be due to the difference
in defining multimorbidity.
Compared to previous studies, this ARIS-
TOPHANES subgroup analysis provides a larger
sample of patients with NVAF and multimor-
bidity from a more representative population,
including both Medicare and commercially
insured patients. The results are consistent with
available RCT literature in showing that NOACs
are associated with favorable benefit/risk profile
when compared to warfarin.
Limitations
For this retrospective observational study, only
statistical associations could be concluded, not
causal relationships. Although cohorts were
matched through PSM, there were potential
residual confounders. As a result of the nature of
claims studies, outcome measures could only be
based on International Classification of Dis-
eases—Ninth Revision—Clinical Modification
(ICD-9-CM) codes without further adjustment
with precise clinical criteria. In addition, labo-
ratory values, such as hemoglobin or interna-
tional normalized ratio (INR) measurements,
are not available in the dataset so time in ther-
apeutic range for patients prescribed warfarin
was indeterminable. Nonetheless, the inclusion
of patients with potentially poorer quality
control of warfarin therapy in everyday clinical
practice may enable the study findings to better
reflect real-world situations. Additionally, pre-
viously verified mortality information was only
available for Medicare patients, and although
62% of stroke deaths occur outside of an acute
hospital setting, it is unlikely that the propor-
tion of deaths would differ by cohort [20, 21].
This study used both the distribution of
comorbidities at baseline and previously pub-
lished ARISTOTLE trial subgroup analyses to
define multimorbidity, but definition of multi-
morbidity differs from some other studies and
presents a challenge to compare our findings
with those of other studies. While all patients
were required to have at least six comorbidities,
the severity of conditions remained unknown
and may not be equal among patients. More-
over, unobserved heterogeneity may exist
across the five data sources. Although some of
the datasets contain information from different
insurance plans that do not overlap at the plan
level, others are employer-based claims datasets
which may contain duplicate patient records
when pooled together. However, the number of
such duplicates is likely to be low—on the basis
of a published estimate of 0.5%—and therefore
unlikely to have any significant effect on the
results [22]. Finally, the results may not reflect
the overall multimorbid NVAF population in
the USA because the study did not include
Adv Ther (2021) 38:3166–3184 3181
uninsured patients and those solely covered by
other public health insurance plans.
CONCLUSIONS
In the largest observational study of patients
with NVAF and multimorbidity, we show that
among patients with NVAF and six or more
comorbid conditions, NOACs were associated
with varying risk of stroke/SE and MB compared
to warfarin and to each other. Rather than a
‘‘one drug fits all’’ approach, our results may be
useful for selecting appropriate OAC treatment
for multimorbid patients.
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